share_log

B. Riley Securities Maintains Neutral on Kymera Therapeutics, Raises Price Target to $36

Benzinga ·  Jul 10 01:59

B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Neutral and raises the price target from $31 to $36.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment